(Alliance News) - EKF Diagnostics Holdings PLC on Monday said it has inked an agreement to acquire technology assets from Kiruna, Sweden-based Beep Insights AB as it looks to strengthen its Sports Performance products range.
The Cardiff, Wales-based diagnostics and biotechnology company said the asset purchase agreement is in relation to the company's Beep Insights Technology. This, said EKF, is an application that combines data from sports performance wearables connected through Bluetooth, with real-time glucose and lactate tracking.
As such, said EKF, it is able to provide personalised metrics to improve sports performance training. EKF said the acquisition will support its Lactate Scout Sport product, which it noted is compatible with the Beep Insights application
EKF added that Beep Insights Chief Executive Peter Alex is set to join the EKF team following the asset purchase, looking into the development of AI within performance training.
The financial terms of the acquisition were not disclosed.
Shares in EKF were down 2.6% at 23.58 pence on Monday afternoon in London.
EKF CEO Gavin Jones said: "Whilst working with Beep Insights we have been highly impressed with how well their data handling application seamlessly connects with our handheld Lactate Scout Sport device, enabling, fast and accurate lactate threshold testing for sports performance athletes at all levels.
"The acquisition of this technology is an exciting step forward for EKF's Sports Performance division as we look to enable athletes of all abilities access to data to drive improved training outcomes."
By Christopher Ward, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2026 Alliance News Ltd. All Rights Reserved.


(Alliance News) - Ultimate Products PLC on Thursday said it expects full-year revenue to be slightly ahead of market consensus despite continued subdu...


(Alliance News) - DP Poland PLC on Thursday reported increased pretax losses in 2025 despite strengthened trading towards the end of the year.


Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Pretax loss narrows to GBP346,577 in the six months ended March 31, fr...